In recognition of Rare Disease Day 2026, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that its NETHERTON NOW awareness campaign has achieved nearly 2 million video views and more than 24 million impressions globally since its launch in February 2025. The campaign aims to amplify the voices of patients, caregivers, and clinicians affected by Netherton Syndrome, a rare genetic skin disorder with no approved treatment or cure.
Netherton Syndrome is caused by mutations in the SPINK5 gene, leading to excessive skin shedding, chronic inflammation, recurrent infections, dehydration, and severe disruption of the skin barrier. The disease can be life-threatening, particularly in infancy, with an estimated 10–20% of newborns not surviving. Those who survive often face lifelong complications and significant quality-of-life burdens.
Denise Carter, Co-Founder and Chief Operating Officer of Quoin Pharmaceuticals, stated, "When we launched NETHERTON NOW at the beginning of Rare Disease Month last year, we hoped it would resonate, but the response has far surpassed anything we anticipated. Individuals who had previously lived in silence with their suffering now have a platform to share their stories, connect with one another, and help bring greater understanding of Netherton Syndrome to the broader medical and advocacy communities."
In conjunction with Rare Disease Day, the campaign released a new video titled "If There Was a Cure," featuring patients and families reflecting on what meaningful treatment progress would mean in their lives. The video underscores the daily realities of living with Netherton Syndrome and the shared hope for improved treatment options. The full video can be viewed here.
Dr. Michael Myers, Co-Founder and Chief Executive Officer of Quoin Pharmaceuticals, emphasized, "As we listen to the voices of this community, we are reminded that this growing awareness must be accompanied by action. Our responsibility extends beyond just creating visibility. It includes advancing rigorous clinical research, pursuing regulatory pathways with discipline, and working to ensure broad access to potential treatments."
Quoin's lead investigational candidate, QRX003, is currently being evaluated in late-stage pivotal clinical trials for Netherton Syndrome. The company remains committed to addressing the significant unmet medical needs of patients and families impacted by this devastating disease.
For more information about Rare Disease Day, visit www.rarediseaseday.org. To learn more about Netherton Syndrome and the NETHERTON NOW awareness campaign, visit https://nethertonnow.com.
